Dr. David Spigel Discusses the Evolving Non-Small Cell Lung Cancer Treatment Landscape
2 Views
administrator
07/14/23
David Spigel, MD, director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses the evolving landscape for treating patients with refractory non-small cell lung cancer (NSCLC), specifically with the EGFR targeted tyrosine kinase inhibitor (TKI) erlotinib (Tarceva).
To find out more, visit http://www.onclive.com/confere....nce-coverage/2012-th
-
Category
Show more
Facebook Comments
No comments found